Morressier announces $16.5m Series B to lead the fight for research integrity

This growth investment follows the companys Series A round communicated in May 2021, and will be topped up with further funding for acquisition opportunities.Morressier counts some of the industrys leading players in the scientific ecosystem as customers, including: IOP Publishing, AAAS, ASCE, APS, and Mayo Clinic. The company will use its Series B growth capital for continued product innovation, scaling its go-to-market activities, including the institutional and corporate market, and to expand partnerships with leading research integrity vendors.Sami Benchekroun, Morressier co-founder and CEO: Attracting such strong support from investors in this climate is the ultimate validation that Morressier is doing critical work. The company already offers scientific researchers a suite of pre-submission checks to ensure submission completeness, quality, and help comply with industry standards. One in five articles published in journals may contain faked data produced by paper mills that are paid to fabricate scientific submissions, according to a study by German researchers who used new techniques to red flag problematic papers.Othman Altalib, Morressier Chief Growth Officer: Deepening our partnerships across the scholarly publishing industry is core to Morressiers growth: it ensures that we remain aligned with and supportive of stakeholder needs. By building a new submission and peer review system around the needs of the research community, we can optimise our workflows in ways that will make a real difference.